Blueprint Medicines Says FDA Approves Gavreto to Treat Thyroid Cancer
02 December 2020 - 8:12AM
Dow Jones News
By Stephen Nakrosis
Blueprint Medicines Corp. on Tuesday said the U.S. Food and Drug
Administration approved Gavreto as a treatment for certain types of
thyroid cancer.
The company said the FDA approved Gavreto, or pralsetinib, as a
treatment for patients with RET-altered thyroid cancers.
Blueprint Medicines said it is co-commercializing Gavreto in the
U.S. with Genentech, under Blueprint's collaboration with
Roche.
"In the Phase 1/2 ARROW trial, Gavreto showed durable efficacy
and was generally well-tolerated in patients with RET-altered
thyroid cancers with or without prior systemic therapy," Blueprint
said.
"Earlier this year, the FDA granted accelerated approval to
Gavreto for the treatment of adults with metastatic RET
fusion-positive non-small cell lung cancer as detected by an FDA
approved test," the company added.
At 3:36 p.m. EST, Blueprint Medicines' shares were trading 2.5%
lower on the Nasdaq at $105.83. Year to date, the stock is up over
31%.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 01, 2020 15:57 ET (20:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Apr 2024 to May 2024
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From May 2023 to May 2024